Maamaa Teitei 540737-29-9 Tofacitinib citrate mo JAK Pathway Inhibitor
Huaingoa | Tofacitinib Citrate |
Nga kupu taurite | (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3 -propanetricarboxylate;CP 690500-10;CP 690550-10;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetriccarboxylate |
CAS No. | 540737-29-9 |
Te ahua | He ma ki te paura ma |
Tātai rāpoi | C16H20N6OC6H8O7 |
Taumaha rāpoi | 504.50 |
Taupānga | Te karaehe rongoa, kaupapa rangahau ranei |
Te takai | Ka rite ki to tono |
Rokiroki | Whakaorangia i roto i nga ipu kiki, kare-marama i te waahi makariri |
Tofacitinib Citrate (CAS #540737-29-9) | ||
NGA MEA | PAERERE | HUA |
Te ahua | He ma ki te paura ma | Te paura ma |
Tautuhinga | HPLC;IR;HNMR | Ka tutuki |
Wairewa | Wairewa i roto i te DMSO i 100mg/ml, tino iti te wairewa i roto i te waihā, iti wairewa i roto i te wai etc. | Ka tutuki |
Ngaronga i te whakamaroke | ≤0.5% | 0.12% |
Te toenga i runga i te mura | ≤0.1% | 0.05% |
Nga konganuku taumaha | ≤10ppm | Ka tutuki |
Nga Taonga Paanga | Diastereomer (RS+SR) ≤0.1% Te poke kotahi ≤0.15% Tapeke poke ≤1.0% | 0.05% 0.14% 0.18% |
Enantiomorphism Isomers | ≤0.2% | Ka tutuki |
Wairewa toenga | Ewaro ≤5000ppm Mewaro ≤3000ppm Toluene ≤890ppm | Ka tutuki |
Ihirangi Citrate | 36.2%~40% | 37.8% |
Maamaa | ≥99.0% | 99.38% |
Te whakamatautau | 60.68%~63.16% o Tofacitinib INN 98%~102% o Tofacitinib Citrate INN | 62.04%
99.12% |
Whakamutunga: Ka tutuki |
Nga korero a te Kamupene
√ Ko nga wheako katoa o te paparanga whakahaere i roto i te wheketere me nga kaitoi mohio nga akonga; √ Ko te kounga tonu to maatau whakaaro nui, te punaha QC tino tika; √ 11 tau te mohio ki te kawe i te roopu hoko; √ taiwhanga R&D motuhake; √ E rua nga awheawhe GMP roa kua hainatia; √ He nui nga rawa o nga wheketere mangere mo te kaupapa kua whakaritea; √ He roopu mahi Kairangi me te huarahi rite.Tuhia to korero ki konei ka tukuna mai ki a matou